Determining the in vivo role of chronic inflammatory burden through quantification of the GlycA biomarker in a spectrum of inflammatory and immuno-depressed pathologies KU Leuven
Laboratory of Clinical and Epidemiological Virology (Rega Institute), UZ Leuven, Université d'Aix-Marseille
A novel biomarker called GlycA is a summary measure for the concentration of specific inflammation-related glycoproteins and the degree to which they are acetylated; hence its name Glycoprotein Acetylation. Previous studies have shown that this biomarker is an excellent summary measure for chronic inflammatory burden: increased GlycA is associated with short term all-cause mortality, cardiovascular disease risk, metabolic syndrome and disease ...